RxDoctor Payments Data

Lorena Layrisse Landaeta, MD

Internal Medicine · Rolling Hills Estates, CANPI 1538589965

Payments from drug & device makers

$1,157in general payments, 2019–2025

Across 46 payments — averaging $25.16 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GSK$180
  • Pfizer$129
  • Gilead$120
  • Amgen$117
  • Novo Nordisk$109
  • Lilly USA, LLC$106
  • plus $396 from 9 others

What the payments were for

  • Food & beverage$1,157100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,157 in reported general payments places this provider in the 75th percentile of 13,581 internal medicine providers in California.

See all internal medicine providers in California

Medicare billing

Part B allowed, 2024
$191,110
Medicare patients
424
Services billed
1,846

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban54$54,685
LinzessLinaclotide28$22,716
XareltoRivaroxaban18$21,007
JardianceEmpagliflozin15$20,518
JanuviaSitagliptin Phosphate14$17,366
Repatha SureclickEvolocumab11$10,974
OzempicSemaglutide11$10,185
Atorvastatin Calcium471$4,989
Levothyroxine Sodium286$3,615
Losartan Potassium235$3,437
Rosuvastatin Calcium190$3,083
SynthroidLevothyroxine Sodium42$2,691
Metoprolol Succinate159$2,637
Amlodipine Besylate272$1,978
Icosapent Ethyl23$1,730

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$129$54,68554 claims
Boehringer IngelheimJardiance$25$20,51815 claims
MerckJanuvia$48$17,36614 claims
Novo NordiskOzempic$109$10,18511 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 13,581 internal medicine providers in California.

Other internal medicine in Rolling Hills Estates

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →